08:51 AM EDT, 08/12/2024 (MT Newswires) -- Satellos Bioscience ( MSCLF ) on Monday said latest canine data involving its lead candidate SAT-3247 (for treatment of Duchenne muscular dystrophy) is showing promising results.

The company said the latest results from the two dystrophic dogs, updated Monday, showed improvement in muscle force over baseline of 195% at the four-month point.

Satellos expects to dose the first participant in a Phase 1a clinical trial in the third quarter to evaluate the safety and pharmacokinetic properties of SAT-3247 in healthy human volunteers.

The company said its second-quarter net loss widened to $6 million, or $0.05 per share, from $4.1 million, or $0.05 per share, last year. The increase was due to higher research and development (R&D) expenses related to higher headcount and R&D activities associated with SAT-3247.